Strategies towards a longer acting factor VIII. (Q36473043)

14 August 2017

1 reference

title

Strategies towards a longer acting factor VIII. (English)

1 reference

14 August 2017

Saenko EL

1

1 reference

14 August 2017

Pipe SW

series ordinal

2

1 reference

14 August 2017

publication date

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

12 Suppl 3

1 reference

14 August 2017

page(s)

42-51

1 reference

Comprehensive care for haemophilia around the world

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

21 January 2018

WFH: back to the future

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Barriers to compliance with prophylaxis therapy in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Optimizing factor prophylaxis for the haemophilia population: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Pegylation: engineering improved biopharmaceuticals for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

PEGylation, successful approach to drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Catabolism of the coagulation factor VIII: can we prolong lifetime of f VIII in circulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

The size of human factor VIII heterodimers and the effects produced by thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Peptide and protein PEGylation: a review of problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Bioengineering of coagulation factor VIII for improved secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Polysialylated insulin: synthesis, characterization and biological activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

The promise and challenges of bioengineered recombinant clotting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Interaction between factor VIII and LDL receptor-related protein. Modulation of coagulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2006.01260.X

10.1111/J.1365-2516.2006.01260.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference